Given the high prevalence of cirrhosis, the abovementioned studies suggest that ammonia-lowering approaches, NF-κB inhibitors, myostatin inhibitors, and anaplerotic substrates against mitochondrial dysfunction are potential therapeutics to counteract sarcopenia in chronic liver diseases. This evidence concerns the gene MSTN and sarcopenia.